



PHARMACEUTICAL ANALYTICAL REVIEW OF SORAFENIB

Dr. Osman Ahmed*¹, Alufa Tahreem¹ and Dr. Anas Rasheed²

¹Department of Pharmaceutical Analysis, Deccan School of Pharmacy, Hyderabad.

²CSO, Gaelib Medications Private Limited, Hyderabad.



*Corresponding Author: Dr. Osman Ahmed

Department of Pharmaceutical Analysis, Deccan School of Pharmacy, Hyderabad.

Article Received on 06/11/2024

Article Revised on 26/11/2024

Article Accepted on 16/12/2024

ABSTRACT

Background: Sorafenib is an oral multi-kinase inhibitor used for treating advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Despite its efficacy, Sorafenib's chemical complexity and susceptibility to degradation under stress conditions necessitate robust analytical methodologies. Effective quality control is critical to ensuring its safety, potency, and stability in pharmaceutical formulations. **Aim:** To explore and review the various analytical methods developed for Sorafenib, focusing on chromatographic techniques, impurity profiling, and stability-indicating studies to support regulatory compliance and quality assurance. **Research Methodology:** This review highlights chromatographic methods such as HPLC and UPLC, with emphasis on mobile phase optimization, forced degradation studies, and impurity profiling. Spectroscopic methods like UV-Vis, FTIR, NMR, and MS are discussed for their roles in structural elucidation and degradation product identification. Stability studies conducted under acidic, basic, oxidative, thermal, and photolytic stress conditions are detailed to assess Sorafenib's behavior under various environmental challenges. **Conclusion:** Advanced analytical methods, including UPLC and LC-MS/MS, provide robust platforms for impurity profiling and stability evaluation of Sorafenib. These approaches ensure compliance with regulatory standards, supporting its safe and effective use in pharmaceutical applications.

KEYWORDS: Sorafenib, Impurity profiling, Stability studies.

INTRODUCTION

Sorafenib is an oral multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and thyroid cancer. By targeting multiple kinases involved in tumor cell proliferation and angiogenesis, Sorafenib plays a pivotal role in the management of these malignancies. Despite its widespread therapeutic use, its complex chemical structure and susceptibility to degradation necessitate robust analytical methods for quality assurance and regulatory compliance.

Analytical chemistry in the pharmaceutical industry ensures the identity, purity, potency, and stability of drugs. This is particularly important for Sorafenib due to its degradation under various stress conditions, which can lead to the formation of impurities that compromise its efficacy and safety. This review provides an in-depth discussion of the analytical methods developed for Sorafenib, with a focus on chromatographic techniques, impurity profiling, and stability studies.

Chemical Structure and Physicochemical Properties: Sorafenib (chemical name: N-(3-trifluoromethyl-4-

chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yloxy) phenyl) urea) has a molecular weight of 464.82 g/mol. It is slightly soluble in water and exhibits higher solubility in organic solvents like methanol and acetonitrile. These properties influence the selection of analytical techniques, particularly in chromatographic separations.

Analytical Challenges

The primary challenges in analyzing Sorafenib include

- Degradation under Stress Conditions:** Sorafenib is prone to hydrolysis, oxidation, and photolysis, requiring stability-indicating methods for detecting degradation products.
- Impurity Profiling:** Regulatory authorities mandate impurity identification and quantification to ensure safety and efficacy.
- Matrix Interference:** The analysis of Sorafenib in biological fluids or complex formulations often involves interference from excipients or endogenous substances.
- Sensitivity Requirements:** Low detection and quantification limits are critical for impurity analysis and pharmacokinetic studies.

CHROMATOGRAPHIC METHODS

High-Performance Liquid Chromatography (HPLC):

HPLC remains a cornerstone technique for the analysis of Sorafenib due to its versatility and ability to separate drug components from impurities. Various studies have reported the use of reverse-phase HPLC (RP-HPLC) with C18 columns for this purpose.

- **Mobile Phase Composition:** Methanol and acetonitrile are commonly used in combination with aqueous buffers to achieve optimal separation. For example, methanol: acetonitrile (55:45 v/v) with a pH-adjusted buffer enhances peak resolution.
- **Detection Wavelength:** Sorafenib exhibits maximum absorbance at 240 nm, making UV-visible detection a preferred method.
- **Validation Parameters:** HPLC methods for Sorafenib are validated for precision, accuracy, linearity, specificity, robustness, and system suitability.

Ultra-Performance Liquid Chromatography (UPLC):

UPLC offers enhanced resolution, reduced run times, and lower solvent consumption compared to traditional HPLC.

- **Stationary Phase:** C18 columns with smaller particle sizes (1.7 μm) are employed for superior separation.
- **Forced Degradation Studies:** UPLC methods have been developed to assess Sorafenib under acidic, basic, oxidative, wet heat, and photolytic conditions, revealing degradation products effectively.
- **Impurity Profiling:** The higher sensitivity of UPLC facilitates the detection and quantification of impurities at trace levels, meeting stringent regulatory requirements.

Gas Chromatography (GC): Although not commonly used for Sorafenib due to its limited volatility, GC can be employed for residual solvent analysis in bulk drug substances. The method involves derivatization to enhance volatility and detectability.

SPECTROSCOPIC TECHNIQUES

UV-Visible Spectroscopy: UV spectroscopy is frequently employed for the preliminary quantification of Sorafenib due to its simplicity and cost-effectiveness. The absorption maximum at 240 nm serves as a reliable parameter for its detection.

Fourier Transform Infrared (FTIR) Spectroscopy: FTIR is used to identify functional groups in Sorafenib and its degradation products. Characteristic peaks corresponding to the urea and phenyl functional groups provide structural insights.

Nuclear Magnetic Resonance (NMR) Spectroscopy: NMR spectroscopy is applied for the structural elucidation of Sorafenib and its impurities. It offers detailed information about the chemical environment of atoms within the molecule.

Mass Spectrometry (MS): MS, often coupled with chromatographic techniques (LC-MS), is utilized for molecular weight determination, structural elucidation, and impurity profiling. LC-MS/MS is particularly valuable in pharmacokinetic studies to quantify Sorafenib in biological matrices.

Stability Studies: Stability studies are essential for determining the shelf life and storage conditions of Sorafenib. Stability-indicating methods differentiate the drug from its degradation products under forced degradation conditions, including:

1. **Acidic Hydrolysis:** Conducted using HCl solutions, revealing degradation via hydrolysis of the urea moiety.
2. **Basic Hydrolysis:** Performed using NaOH solutions, leading to cleavage of susceptible bonds.
3. **Oxidation:** Involves exposure to hydrogen peroxide, resulting in oxidative degradation.
4. **Thermal Stress:** Evaluates stability under elevated temperatures, mimicking accelerated storage conditions.
5. **Photolytic Degradation:** Assesses the impact of light exposure on drug stability.

Validation of Analytical Methods: Validation ensures the reliability and reproducibility of analytical methods. Key validation parameters for Sorafenib analysis include:

1. **Linearity:** Demonstrated over a concentration range (e.g., 8–40 $\mu\text{g/mL}$), with correlation coefficients above 0.998.
2. **Precision:** Intraday and inter day variations yield %RSD values within acceptable limits (<2%).
3. **Accuracy:** Recovery studies at different spiking levels confirm recoveries close to 100%.
4. **Specificity:** The ability to separate Sorafenib from impurities and degradation products.
5. **LOD and LOQ:** Limits of detection and quantification ensure sensitivity, with values as low as 0.838 $\mu\text{g/mL}$ and 2.540 $\mu\text{g/mL}$, respectively.
6. **Robustness:** Minor changes in chromatographic conditions (e.g., flow rate, temperature) do not significantly affect method performance.

Impurity Profiling: Regulatory guidelines, such as ICH Q3A and Q3B, mandate the identification and quantification of impurities in drug substances and products. Impurity profiling for Sorafenib involves:

1. **Structural Characterization:** MS and NMR techniques are used to identify unknown impurities.
2. **Quantification:** Chromatographic methods quantify impurities at trace levels (<0.1%).
3. **Toxicological Evaluation:** Impurities are assessed for potential toxicity to ensure patient safety.

Applications in Pharmaceutical Analysis

1. **Quality Control:** Routine analysis of Sorafenib in bulk and finished products to ensure compliance with pharmacopeial standards.

2. **Stability Testing:** Monitoring degradation and ensuring appropriate shelf-life assignments.
3. **Pharmacokinetics:** Quantification of Sorafenib in plasma and other biological matrices for drug metabolism and pharmacokinetic studies.
4. **Regulatory Submissions:** Supporting documentation for new drug applications (NDAs) and abbreviated NDAs (ANDAs).

Challenges and Future Perspectives

1. **Matrix Complexity:** Developing methods to address interference from biological fluids or formulation excipients.
2. **Emerging Technologies:** The application of advanced techniques such as capillary electrophoresis, microfluidics, and high-resolution MS for enhanced analysis.
3. **Green Analytical Chemistry:** Emphasizing eco-friendly solvents and methods to minimize environmental impact.

CONCLUSION

The analytical evaluation of Sorafenib plays a crucial role in ensuring its quality, efficacy, and safety. Advanced techniques like UPLC and LC-MS/MS provide robust platforms for impurity profiling, stability studies, and pharmacokinetic analysis. Continuous advancements in analytical methodologies will further enhance the accuracy, sensitivity, and eco-friendliness of Sorafenib analysis, aligning with the growing regulatory and environmental expectations.

REFERENCES

1. Y. C. Mayur*, Osman Ahmad, V. V.S. Rajendra Prasad, M. N. Purohit, N. Srinivasulu, S. M. Shanta Kumar, "Synthesis of 2-Methyl N10 -Substituted Acridones as Selective Inhibitors of Multidrug Resistance (MDR) Associated Protein in Cancer Cells". Medicinal Chemistry, Bentham Science Publishers, 2008; 4(5): 457-465(9).
2. Osman Ahmed*, Pankaj Sharma, Jaya Sharma, "Synthesis and Pharmacological Study of Azetidinone Derivatives" International Journal of Pharmaceutical Science & Education, 2013; 11-18.
3. Osman Ahmed*, Pankaj Sharma, Jaya Sharma, Dr. Indrajeet Singhvi, "Synthesis and Anticonvulsant Activity of Some Substituted Azetidinone Derivatives" Asian Journal of Pharmaceutical Research and Development, 2013; 5.
4. Osman Ahmed*, Dr. Md Salahuddin, Vinutha. K, Pankaj Sharma. "Design, Synthesis and Biological Evaluation of Some Novel Substituted Thiazolidinone Derivatives as Potent Antihyperglycemic Agents". International Journal of Pharmaceutical Research Scholars, 2013; 2(3).
5. Osman Ahmed*, Md Salahuddin, Pankaj Sharma, Indrajeet Singhvi "Synthesis and biological investigations of some new thiazolidinone derivatives as anti-tubercular agents", American Journal of Pharmtech Research, 2013; 3: 193-201.
6. Osman Ahmed*, Md. Salahuddin, Iffath Rizwana, M.A.Aleem, Pankaj Sharma, "Synthesis, Characterization and Biological Evaluation of Novel thiazolidinone derivatives as Anti-inflammatory Agents", Indo American Journal of Pharmaceutical Research, 2013; 3(10): 8121-8126.
7. Osman Ahmed*, Pankaj Sharma, Indrajeet Singhvi. "Synthesis and Anti-Hyperglycemic activity of Some Novel Thiazolidinone Derivatives". Indo American Journal of Pharmaceutical Research, 2014; 4(02): 1008-1014.
8. Osman Ahmed*, Pankaj Sharma, Indrajeet Singhvi. "Anticonvulsant Activity of Some Novel Substituted Thiazolidinone Derivatives against Maximal Electro Shock Induced Seizure". International Journal of Pharmaceutical Research Scholars, 2014; 3(1): 289-294.
9. Osman Ahmed*, Mohd Haseeb Ur Rahman, Abdul Najeeb, Sk. Md. Noorullah, S.A.Azeez Basha, Design, "Synthesis and Anti-inflammatory activity of certain fused Novel Thienopyrimidines Derivatives", International Journal of Pharmaceutical Research Scholars, 2013; 2(4): 82-87.
10. Syed Aamer Ali, SK Danda, Syed Abdul Azeez Basha, Rasheed Ahmed, Osman Ahmed, Mohd Muqtader Ahmed. "Comparision of uroprotective activity of reduced glutathione with Mesna in Ifosfamide induced hemorrhagic cystitis in rats". Indian Journal of Pharmacology, 2014; 46: 105-108.
11. Osman Ahmed*, Syed Azeemuddin Razvi, T K Md Rayees, M A Nafay Shoeb, Md Salahuddin. "Synthesis Characterization and Anti-inflammatory activity of some substituted pyrimidine derivatives". Indo American Journal of Pharmaceutical Research, 2014; 4(05): 2301-2306. DOI: 10.1044/1980-iajpr.14369.
12. Osman Ahmed*, Farhana Begum, Nishat Fatima, Md. Salahuddin. "Synthesis and Biological Activity of Some Novel Pyrimidine Derivatives". International Journal of Pharmaceutical Research Scholars, 2014; 3(4): 103-108.
13. Ms. Farhana Begum, Osman Ahmed, Md. Salahuddin, Nishat Fatima. "Synthesis, Characterization and Anti-Hyperglycemic Activity of Novel Pyrimidine Derivatives". Indo American Journal of Pharm Research, 2014; 4(11): 5501-5506. DOI: 10.1044/1980-iajpr.141042
14. Osman Ahmed*, Mehruq Fatima, Juveriya Parveen, Asma Farheen, Ayesha Binth Saleh, Dr. Syed Mahmood Ahmed. Changes in Pulmonary Function Test (PFT) Before and After Adding Tiotropium Bromide to the Ongoing Therapy of Severe Persistant Asthmatics. Indo American Journal of Pharm Research, 2015; 5(01). DOI: 10.1044/1980-iajpr.141266.
15. Mohd Khader, Mohd Mahboob Shareef, Syeda Huda Noorain, Osman Ahmed. Synthesis, Characterization and Biological Activity of Some Novel Pyrimidine

- Derivatives. *Indo American Journal of Pharm Research*, 2015; 5(03).
16. Fayeza Batool, Osman Ahmed, Anas Rasheed. An Assay Method for the Simultaneous Estimation of Acetaminophen and Tramadol using RP-HPLC Technology. *Indo American Journal of Pharmaceutical Research*, 5(7): 2605-2610.
 17. Fayeza Batool, Osman Ahmed, Anas Rasheed. A Stability Indicating Method for the Simultaneous Estimation of Acetaminophen and Tramadol in Pharmaceutical Dosage Form. *American Journal of PharmTech Research*, 2015; 5(04): 674-683.
 18. Humeera Rafeeq, Talath Fatima, Afiya Ansari, Osman Ahmed. Personalized Medicine - A Boon For Treating Rheumatoid Arthritis. *Indo American Journal of Pharmaceutical Research*, 5(8).
 19. Humeera Rafeeq, Osman Ahmed, M.A Khaleq, Samee A, Amer M. Progress In The Treatment of Neuroblastoma. *Indo American Journal of Pharmaceutical Research*, 5(8).
 20. Talath Fatima, Osman Ahmed, Amer Mahboob, Afiya Ansari, Amatullah Fathimah. Personalized Medicine - A Review – Progress In The Treatment of Non-Small Cell Lung Cancer (NSCLC) In A New Era of Personalised Medicine. *Indo American Journal of Pharmaceutical Research*, 5(8).
 21. Talath Fatima*, Osman Ahmed, Afiya Ansari, Amatullah Fathimah, Amer Mahboob. Novel Therapeutic Approaches to a Chronic Inflammatory Disorder – Asthma. *International Journal of Pharmaceutical Research Scholars*, 2015; 4(3): 112-117.
 22. Humeera Rafeeq*, Osman Ahmed, Sohail Ali, Mohd Yunus, Mohd Bilal. A Review on MowatWilson Disorder, *International Journal of Pharmaceutical Research Scholars*, 2015; V-4, I-3: 176-181.
 23. Humeera Rafeeq*, Osman Ahmed, Fayeza Ameen, Amreen Sultana, Maryam Fatima. A Review on Harlequin Ichthyosis. *International Journal of Pharmaceutical Research Scholars*, 2015; 4(3): 189-193.
 24. Anees Begum*, Osman Ahmed. An Assay Method for the Simultaneous Estimation of Albuterol and Ipratropium Bromide using RP- HPLC Technology. *International Journal of Pharmaceutical Research Scholars*, 2016; 5(4): 33-37.
 25. Anas Rasheed*, Osman Ahmed. UPLC Method Optimisation and Validation for the Estimation of Sodium Cromoglycate in Pressurized Metered Dosage Form, *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(2): 18-24, <http://dx.doi.org/10.21477/ijapsr.v2i2.7774>
 26. Anas Rasheed*, Osman Ahmed. UPLC Method Development and Validation for the Determination of Chlophedianol Hydrochloride in Syrup Dosage Form. *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(2): 25-31, <http://dx.doi.org/10.21477/ijapsr.v2i2.7775>
 27. Anas Rasheed*, Osman Ahmed. Validation of a Forced Degradation UPLC Method for Estimation of Beclomethasone Dipropionate in Respules Dosage Form. *Indo American Journal of Pharmaceutical Research*, 2017; 7(05).
 28. Anas Rasheed*, Osman Ahmed. Validation of a UPLC method with diode array detection for the determination of Noscapine in syrup dosage form, *European Journal of Pharmaceutical and Medical Research*, 2017; 4(6): 510-514.
 29. Anas Rasheed*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Triamcinolone in syrup dosage form. *World Journal of Pharmaceutical and Life Sciences*, 2017; 3(4): 200-205.
 30. Anas Rasheed*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Pholcodine in bulk dosage form. *European Journal of Biomedical and Pharmaceutical Sciences*, 2017; 4(6): 572-579.
 31. Anas Rasheed*, Osman Ahmed. Analytical method development and validation for the determination of Codeine in syrup dosage form using UPLC technology. *World Journal of Pharmaceutical and Life Sciences*, 2017; 3(5): 141-145.
 32. Anas Rasheed*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Fluticasone propionate in nasal spray inhaler dosage form. *World Journal of Pharmaceutical and Life Sciences*, 2017; 3(5): 168-172.
 33. Anas Rasheed*, Osman Ahmed. Stability indicating UPLC method optimisation and validation of Acetylcysteine in syrup dosage form. *European Journal of Pharmaceutical and Medical Research*, 2017; 4(7): 485-491.
 34. Anas Rasheed*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Ciclesonide in dry powder inhaler dosage form. *European Journal of Pharmaceutical and Medical Research*, 2017; 4(7): 523-529.
 35. Anas Rasheed*, Osman Ahmed. Analytical stability indicating UPLC assay and validation of Dextromethorphan in syrup dosage form. *European Journal of Pharmaceutical and Medical Research*, 2017; 4(7): 548-554.
 36. Anas Rasheed*, Osman Ahmed. Analytical Development and Validation of a Stability Indicating Method for the Estimation of Impurities in Budesonide Respules Formulation, *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(3): 46-54. <http://dx.doi.org/10.21477/ijapsr.v2i3.8100>.
 37. Anas Rasheed*, Osman Ahmed, Analytical Separation and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in Ipratropium Bromide Respules Formulation, *International Journal of Applied Pharmaceutical Sciences and Research*, 2017; 2(3): 55-63. <http://dx.doi.org/10.21477/ijapsr.v2i3.8101>.
 38. Neha Naaz*, Khaja Uzair ul Hasan, Aaminah Najmus Sahar, Prof. Dr. Osman Ahmed. Plights and

- Predicaments in the Pharmacy Industry. *Indo American Journal of Pharmaceutical Research*, 2017; 7(11).
39. Syed Vakeeluddin*, Osman Ahmed, Kauser Fathima, Analytical Method Development and Validation for the Simultaneous Estimation of Budesonide and Formoterol in Bulk and Dosage Form Using RP-HPLC Method, *Indo Am. J. P. Sci.*, 2017; 4(07).
 40. Dr. Osman Ahmed*, Syed Vakeeluddin, Kauser Fathima. A Stability Indicating Method for the Simultaneous Estimation of Budesonide and Formoterol in Bulk and Dosage Form. *Indo American Journal of Pharmaceutical Research*.
 41. Kauser Fathima*, Dr. Osman Ahmed, Syed Vakeeluddin, Analytical Method Development and Validation for the Simultaneous Estimation of Ofloxacin and Metronidazole in Bulk and Dosage Form Using RP-HPLC, *Indo Am. J. P. Sci.*, 2017; 4(07).
 42. Dr. Osman Ahmed*, Kauser Fathima, Syed Vakeeluddin. A Stability Indicating Method for the Simultaneous Estimation of Ofloxacin and Metronidazole in Bulk and Dosage Form. *Indo American Journal of Pharmaceutical Research*, 2018; 8(01).
 43. Mohd Shafi, Osman Ahmed, Anas Rasheed, Validation Of A UPLC Method With Diode Array Detection Using C18 Column For The Determination Of Fluorometholone In Parenteral Dosage Form, *Indo Am. J. P. Sci.*, 2018; 05(07).
 44. Validation Of A Forced Degradation Uplc Method For Estimation Of Glibenclamide In Oral Dosage Form, Dr. Osman Ahmed, Mohd Kareem Ahmed and Dr. Anas Rasheed. *World Journal of Pharm. and Life Sci.*, 2019; 5(10): 74-82.
 45. Evaluation and Validation Of A UPLC Method For Simultaneous Estimation Of Glimepiride, Metformin And Voglibose In Oral Dosage Form, Mohd Kareem Ahmed, Dr. Osman Ahmed and Dr. Anas Rasheed. *European Journal Of Biomedical and Pharmaceutical Sciences*, 2019; 6(13): 329-337.
 46. Stability Indicating Method Evaluation And Validation For Simultaneous Estimation Of Glimepiride, Metformin And Voglibose In Oral Dosage Form Using LCMS, Mohd. Kareem Ahmed, Dr. Osman Ahmed and Dr. Anas Rasheed *European Journal Of Biomedical and Pharmaceutical Sciences*, 2019; 6(13): 338-349.
 47. Stability Indicating Method Evaluation And Validation For Simultaneous Estimation Of Metformin And Sitagliptin In Oral Dosage Form Dr. Osman Ahmed, Mohd Kareem Ahmed and Dr. Anas Rasheed, *European Journal Of Pharmaceutical And Medical Research*, 2019; 6(12): 494-502.
 48. Evaluation And Validation Of A UPLC Method For Simultaneous Estimation Of Metformin And Sitagliptin In Oral Dosage Form Dear Dr. Osman Ahmed, Mohd Kareem Ahmed and Dr. Anas Rasheed *European Journal Of Pharmaceutical And Medical Research*, 2019; 6(12): 494-502.
 49. Evaluation And Validation Of A UPLC Method For Estimation Of Amoxycylav In Oral Dosage Form. Dr. Osman Ahmed*, Sumaiya Fatima and Dr. Anas Rasheed, *World Journal of Pharm. and Life Sci.*, 2020; 6(9): 107-113.
 50. RESPULES *Sumaiya Fatima, Dr. Osman Ahmed and Dr. Anas Rasheed, *World Journal of Pharm. and Life Sci.*, 2020; 6(9): 68-77.
 51. POLYMORPHISM Sumaiya Fatima*, Dr. Osman Ahmed and Dr. Anas Rasheed *World Journal of Pharm. and Life Sci.*, 2020; 6(9): 78-93.
 52. Chemical force degradation assay method evaluation for simultaneous estimation of amoxicillin and potassium clavulanate in oral dosage form Sumaiya Fatima*, Dr. Osman Ahmed and Dr. Anas Rasheed, *European Journal Of Pharmaceutical and Medical Research*, 2020; 7(9): 320-325.
 53. Characterization of force degradation assay method evaluation for simultaneous estimation of amoxicillin and potassium clavulanate in oral dosage form using UPLC-MS/MSN Sumaiya Fatima*, Dr. Osman Ahmed and Dr. Anas Rasheed *ejbps.*, 2020; 7(9): 285-294.
 54. Evaluation and validation of a uplc method for simultaneous estimation of amoxicillin and potassium clavulanate in oral dosage form. Sumaiya Fatima*, Dr. Osman Ahmed and Dr. Anas Rasheed. *European Journal Of Pharmaceutical And Medical Research*, 2020; 7(9): 326-335.
 55. Spiked force degradation assay method evaluation for estimation of amoxycylav in oral dosage form. Dr. Osman Ahmed*, Sumaiya Fatima and Dr. Anas Rasheed. *World Journal of Pharm. and Life Sci.*, 2020; 6(9): 185-191.
 56. Anas Rasheed Et.Al; Validation Of A Uplc Method With Diode Array Detection Using C18 Column For The Determination Of Fluorometholone In Parenteral Dosage Form, *Indo American Journal Of Pharmaceutical Sciences*, *Iajps.*, 2016; 5(7): 6209-6215.
 57. Anas Rasheed Et.Al; Analytical Method Development And Validation For The Determination Of Fluorometholone Using C8 Column In Parenteral Dosage Form By Uplc Technology, *World Journal Of Pharmaceutical And Life Sciences*, *Wjpls.*, 2018; 4(8): 106-109.
 58. Anas Rasheed Et.Al; Analytical Stability Indicating Uplc Assay And Validation Using C18 Column For Fluorometholone In Parenteral Dosage Form, *World Journal Of Pharmaceutical And Life Sciences*, *Wjpls.*, 2018; 4(8): 110-114.
 59. Anas Rasheed Et.Al; Validation Of A Forced Degradation Uplc Method Using C8 Column For Fluorometholone In Parenteral Dosage Form, *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2018; 5(8): 311-318.
 60. Anas Rasheed Et.Al; Analytical Separation And Characterisation Of Degradation Products Method

- For The Estimation Of Impurities In Fluorometholone In Parenteral Dosage Form, European Journal Of Pharmaceutical And Medical Research, *Ejpmr.*, 2018; 5(8): 319-324.
61. Anas Rasheed Et.Al; Validation Of A Forced Degradation Uplc Method For Estimation Of Glibenclamide In Oral Dosage Form, *World Journal Of Pharmaceutical And Life Sciences*, *Wjpls.*, 2019; 5(10): 74-82.
 62. Anas Rasheed Et.Al; Evaluation And Validation Of A Uplc Method For Simultaneous Estimation Of Glimepiride, Metformin And Voglibose In Oral Dosage Form, *European Journal Of Biomedical And Pharmaceutical Sciences*, *Ejbps.*, 2019; 13(6): 329-337.
 63. Anas Rasheed Et.Al; Stability Indicating Method Evaluation And Validation For Simultaneous Estimation Of Glimepiride, Metformin And Voglibose In Oral Dosage Form Using Lcms, *European Journal Of Biomedical And Pharmaceutical Sciences*, *Ejbps.*, 2019; 6(13): 338-349.
 64. Anas Rasheed Et.Al; Evaluation And Validation Of A Uplc Method For Simultaneous Estimation Of Metformin And Sitagliptin In Oral Dosage Form, *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2019; 6(12): 365-371.
 65. Anas Rasheed Et.Al; Stability Indicating Method Evaluation And Validation For Simultaneous Estimation Of Metformin And Sitagliptin In Oral Dosage Form, *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2019; 6(12): 494-502.
 66. Anas Rasheed Et.Al; Uplc Method Optimisation And Validation For The Estimation Of Sodium Cromoglycate In Pressurized Metered Dosage Form, *International Journal Of Applied Pharmaceutical Sciences And Research*, 2017; 2(2): 18-24.
 67. Anas Rasheed Et.Al; Uplc Method Development And Validation For The Determination Of Chlophedianol Hydrochloride In Syrup Dosage Form *International Journal Of Applied Pharmaceutical Sciences And Research*, 2017; 2(2): 25-31.
 68. Anas Rasheed Et.Al; Analytical Method Development And Validation For The Determination Of Codeine In Syrup Dosage Form Using Uplc Technology, *World Journal Of Pharmaceutical And Life Sciences*, *Wjpls.*, 2017; 3(5): 141-145.
 69. Anas Rasheed Et.Al; Validation Of A Uplc Method With Diode Array Detection For The Determination Of Noscapine In Syrup Dosage Form *European Journal Of Pharmaceutical And Medical Research*, *Ejpmr.*, 2017; 4(6): 510-514.
 70. Anas Rasheed Et.Al; Validation Of A Forced Degradation Uplc Method For Estimation Of Beclomethasone Dipropionate In Respules Dosage Form *Indoamerican Journal Of Pharmaceutical Research*, 2017; 7(05): 8608-8616.